Predict your next investment

HEALTHCARE | Biotechnology
expresson.co.uk

See what CB Insights has to offer

Founded Year

1999

Stage

Series A | Dead

Total Raised

$2.71M

Last Raised

$900K

About ExpressOn Biosystems

Developer of antisense and short interfering ribonucleaic acid (siRNA) technologies. The company's proprietary technology is a fully degenerate short-oligo microarray platform that empirically maps RNA structure and determines knockdown hot-spots for antisense and siRNA design. The company generates revenues from its technology platform through the provision of premium services and technology licenses to pharmaceutical, biotechnology, academic and life sciences customers engaged in functional biology, target validation, probe-design and new lead discovery research and development.

ExpressOn Biosystems Headquarter Location

Logan Building, Roslin BioCentre

Roslin, EH25 9TT,

United Kingdom

44 131 527 4607

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.